{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T22:37:44Z","timestamp":1790030264553,"version":"4.0.1"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,8,19]],"date-time":"2024-08-19T00:00:00Z","timestamp":1724025600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,8,19]],"date-time":"2024-08-19T00:00:00Z","timestamp":1724025600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Klinikum der Universit\u00e4t M\u00fcnchen"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["EJNMMI Rep."],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Objective<\/jats:title>\n                <jats:p>Bone metastases are very common in advanced prostate cancer and can sensitively be detected utilizing PSMA-PET\/CT. Therefore, our goal was to evaluate the suitability of PSMA-PET\/CT-guided metastasis-directed external beam radiotherapy (MDT) as treatment option for patients with biochemical recurrence and oligometastatic bone lesions.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Materials &amp; methods<\/jats:title>\n                <jats:p>We retrospectively examined 32 prostate cancer patients with biochemical recurrence and PSMA-positive oligometastatic disease limited to the bone (<jats:italic>n<\/jats:italic>\u2009=\u20091\u20133). A total of 49 bone lesions were treated with MDT. All patients received a post-radiotherapy PSMA-PET\/CT-Scan. Changes in SUV<jats:sub>max<\/jats:sub>, PSMA-positive tumor volume per lesion and PSA, as well as the correlation between the PET\/CT-interval and SUV<jats:sub>max<\/jats:sub> response were calculated.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>MDT lead to a SUV<jats:sub>max<\/jats:sub> decrease in 46\/49 (94%) of the lesions. The median relative decline of SUV<jats:sub>max<\/jats:sub> was 60.4%, respectively. Based on PSMA-positive lesion volume with a SUV cut-off of 4, 46\/49 (94%) of lesions showed complete response, two (4%) partial response and one lesion (2%) was stable on PSMA-PET\/CT after MDT. Most of the treated patients (56.3%) showed an initial PSA decline at three months and a PSA nadir of median 0.14 ng\/ml after a median time of 3.6 months after MDT. The median relative PSA change at three months after MDT was 3.9%.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>MDT is a very effective treatment modality for prostate cancer bone oligometastases and lesion response to MDT can be assessed using the (semi-)quantitative parameters SUV<jats:sub>max<\/jats:sub> and PSMA-positive lesion volume with established SUV cut-offs.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s41824-024-00212-w","type":"journal-article","created":{"date-parts":[[2024,8,19]],"date-time":"2024-08-19T06:36:53Z","timestamp":1724049413000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["PSMA-PET\/CT response after metastasis-directed radiotherapy of bone oligometastases in prostate cancer"],"prefix":"10.1186","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7026-9203","authenticated-orcid":false,"given":"Gabriel T.","family":"Sheikh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Trapp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina-Sophie","family":"Schmidt-Hegemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Buchner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian G.","family":"Stief","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcus","family":"Unterrainer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang G.","family":"Kunz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clemens C.","family":"Cyran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Freba","family":"Grawe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Astrid","family":"Delker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathias J.","family":"Zacherl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrien","family":"Holzgreve","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lena M.","family":"Unterrainer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Brendel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claus","family":"Belka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minglun","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Rogowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,8,19]]},"reference":[{"key":"212_CR45","doi-asserted-by":"publisher","first-page":"890814","DOI":"10.3389\/fruro.2022.890814","volume":"2","author":"EM Anderson","year":"2022","unstructured":"Anderson EM, McBride SM (2022) The Use of Androgen Deprivation Therapy in Combination with Radiation for localized prostate Cancer. Front Urol 2:890814","journal-title":"Front Urol"},{"issue":"4","key":"212_CR23","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1007\/s00066-017-1239-1","volume":"194","author":"R Baumann","year":"2018","unstructured":"Baumann R et al (2018) Oligometastases in prostate cancer: metabolic response in follow-up PSMA-PET-CTs after hypofractionated IGRT. Strahlenther Onkol 194(4):318\u2013324","journal-title":"Strahlenther Onkol"},{"issue":"2","key":"212_CR28","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1007\/s00259-014-2961-x","volume":"42","author":"R Boellaard","year":"2015","unstructured":"Boellaard R et al (2015) FDG PET\/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol Imaging 42(2):328\u2013354","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"4","key":"212_CR3","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1016\/j.eururo.2016.08.002","volume":"71","author":"P Cornford","year":"2017","unstructured":"Cornford P et al (2017) EAU-ESTRO-SIOG guidelines on prostate Cancer. Part II: treatment of relapsing, metastatic, and castration-resistant prostate Cancer. Eur Urol 71(4):630\u2013642","journal-title":"Eur Urol"},{"issue":"2","key":"212_CR17","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.eururo.2020.09.046","volume":"79","author":"P Cornford","year":"2021","unstructured":"Cornford P et al (2021) EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer. Part II\u20142020 update: treatment of relapsing and metastatic prostate cancer. Eur Urol 79(2):263\u2013282","journal-title":"Eur Urol"},{"issue":"3","key":"212_CR11","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/j.semradonc.2021.03.007","volume":"31","author":"MP Deek","year":"2021","unstructured":"Deek MP, Phillips RM, Tran PT (2021) Local therapies in Oligometastatic and oligoprogressive prostate Cancer. Semin Radiat Oncol 31(3):242\u2013249","journal-title":"Semin Radiat Oncol"},{"issue":"2","key":"212_CR22","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45(2):228\u2013247","journal-title":"Eur J Cancer"},{"issue":"23Supplement","key":"212_CR39","first-page":"5823s","volume":"55","author":"YE Erdi","year":"1995","unstructured":"Erdi YE et al (1995) Threshold estimation in single photon emission computed tomography and planar imaging for clinical radioimmunotherapy. Cancer Res 55(23Supplement):5823s\u20135826s","journal-title":"Cancer Res"},{"issue":"S12","key":"212_CR40","doi-asserted-by":"publisher","first-page":"2505","DOI":"10.1002\/(SICI)1097-0142(19971215)80:12+<2505::AID-CNCR24>3.0.CO;2-F","volume":"80","author":"YE Erdi","year":"1997","unstructured":"Erdi YE et al (1997) Segmentation of lung lesion volume by adaptive positron emission tomography image thresholding. Cancer: Interdisciplinary Int J Am Cancer Soc 80(S12):2505\u20132509","journal-title":"Cancer: Interdisciplinary Int J Am Cancer Soc"},{"key":"212_CR29","doi-asserted-by":"crossref","unstructured":"Fanti S, Hadaschik B, Herrmann K (2020) Proposal for systemic-therapy response-assessment criteria at the time of PSMA PET\/CT imaging: the PSMA PET progression criteria. Soc Nuclear Med. pp. 678\u2013682","DOI":"10.2967\/jnumed.119.233817"},{"key":"212_CR30","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1007\/s00259-020-04934-4","volume":"48","author":"S Fanti","year":"2021","unstructured":"Fanti S et al (2021) Consensus statements on PSMA PET\/CT response assessment criteria in prostate cancer. Eur J Nucl Med Mol Imaging 48:469\u2013476","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"6","key":"212_CR27","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1007\/s00259-017-3670-z","volume":"44","author":"WP Fendler","year":"2017","unstructured":"Fendler WP et al (2017) 68Ga-PSMA PET\/CT: Joint EANM and SNMMI procedure guideline for prostate cancer imaging: version 1.0. Eur J Nucl Med Mol Imaging 44(6):1014\u20131024","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"11","key":"212_CR31","first-page":"1651","volume":"63","author":"A Gafita","year":"2022","unstructured":"Gafita A et al (2022) Novel Framework for treatment response evaluation using PSMA PET\/CT in patients with metastatic castration-resistant prostate Cancer (RECIP 1.0): an International Multicenter Study. J Nucl Med 63(11):1651\u20131658","journal-title":"J Nucl Med"},{"issue":"2","key":"212_CR33","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1002\/pros.22742","volume":"74","author":"G Gandaglia","year":"2014","unstructured":"Gandaglia G et al (2014) Distribution of metastatic sites in patients with prostate cancer: a population-based analysis. Prostate 74(2):210\u2013216","journal-title":"Prostate"},{"issue":"13","key":"212_CR35","doi-asserted-by":"publisher","first-page":"4483","DOI":"10.1007\/s00259-021-05424-x","volume":"48","author":"H Gr\u00fcnig","year":"2021","unstructured":"Gr\u00fcnig H et al (2021) Focal unspecific bone uptake on [18F]-PSMA-1007 PET: a multicenter retrospective evaluation of the distribution, frequency, and quantitative parameters of a potential pitfall in prostate cancer imaging. Eur J Nucl Med Mol Imaging 48(13):4483\u20134494","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"7547","key":"212_CR12","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1038\/nature14347","volume":"520","author":"G Gundem","year":"2015","unstructured":"Gundem G et al (2015) The evolutionary history of lethal metastatic prostate cancer. Nature 520(7547):353\u2013357","journal-title":"Nature"},{"key":"212_CR9","doi-asserted-by":"crossref","unstructured":"Hellman S, Weichselbaum RR (1995) Oligometastases. J Clin Oncol 13(1):8\u201310.","DOI":"10.1200\/JCO.1995.13.1.8"},{"issue":"11","key":"212_CR41","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1007\/s00066-020-01629-5","volume":"196","author":"C Henkenberens","year":"2020","unstructured":"Henkenberens C et al (2020) Efficacy of repeated PSMA PET-directed radiotherapy for oligorecurrent prostate cancer after initial curative therapy. Strahlenther Onkol 196(11):1006\u20131017","journal-title":"Strahlenther Onkol"},{"issue":"1","key":"212_CR50","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1148\/rg.2018170108","volume":"38","author":"MS Hofman","year":"2018","unstructured":"Hofman MS et al (2018) Prostate-specific membrane antigen PET: clinical utility in prostate cancer, normal patterns, pearls, and pitfalls. Radiographics 38(1):200\u2013217","journal-title":"Radiographics"},{"key":"212_CR43","doi-asserted-by":"crossref","unstructured":"Hurmuz P et al (2020) Treatment outcomes of metastasis-directed treatment using 68Ga-PSMA-PET\/CT for oligometastatic or oligorecurrent prostate cancer: Turkish Society for Radiation Oncology group study (TROD 09\u2009\u2013\u2009002). Strahlentherapie und Onkologie, pp. 1034\u20131043","DOI":"10.1007\/s00066-020-01660-6"},{"issue":"5","key":"212_CR34","doi-asserted-by":"publisher","first-page":"687","DOI":"10.2967\/jnumed.117.190157","volume":"58","author":"C Kesch","year":"2017","unstructured":"Kesch C et al (2017) 68Ga or 18F for prostate cancer imaging? J Nucl Med 58(5):687\u2013688","journal-title":"J Nucl Med"},{"issue":"1","key":"212_CR49","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13550-019-0554-1","volume":"9","author":"J Kuten","year":"2019","unstructured":"Kuten J et al (2019) [68Ga] Ga-PSMA-11 PET\/CT for monitoring response to treatment in metastatic prostate cancer: is there any added value over standard follow-up? EJNMMI Res 9(1):1\u20138","journal-title":"EJNMMI Res"},{"issue":"2","key":"212_CR5","doi-asserted-by":"publisher","first-page":"266","DOI":"10.2214\/AJR.18.20699","volume":"213","author":"C Lawhn-Heath","year":"2019","unstructured":"Lawhn-Heath C et al (2019) Single-center prospective evaluation of 68Ga-PSMA-11 PET in biochemical recurrence of prostate cancer. Am J Roentgenol 213(2):266\u2013274","journal-title":"Am J Roentgenol"},{"key":"212_CR8","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.radonc.2020.04.003","volume":"148","author":"Y Lievens","year":"2020","unstructured":"Lievens Y et al (2020) Defining oligometastatic disease from a radiation oncology perspective: an ESTRO-ASTRO consensus document. Radiotherapy Oncology: J Eur Soc Therapeutic Radiol Oncol 148:157\u2013166","journal-title":"Radiotherapy Oncology: J Eur Soc Therapeutic Radiol Oncol"},{"issue":"4","key":"212_CR44","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1038\/nrurol.2015.50","volume":"12","author":"JA Locke","year":"2015","unstructured":"Locke JA et al (2015) Synergistic action of image-guided radiotherapy and androgen deprivation therapy. Nat Reviews Urol 12(4):193\u2013204","journal-title":"Nat Reviews Urol"},{"key":"212_CR2","doi-asserted-by":"crossref","unstructured":"Macedo F et al (2017) Bone metastases: an overview. Oncol Reviews, 11(1)","DOI":"10.4081\/oncol.2017.321"},{"issue":"2","key":"212_CR47","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1007\/s00259-022-05970-y","volume":"50","author":"S Malaspina","year":"2023","unstructured":"Malaspina S et al (2023) Flare on [18F] PSMA-1007 PET\/CT after short-term androgen deprivation therapy and its correlation to FDG uptake: possible marker of tumor aggressiveness in treatment-na\u00efve metastatic prostate cancer patients. Eur J Nucl Med Mol Imaging 50(2):613\u2013621","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"7","key":"212_CR6","doi-asserted-by":"publisher","first-page":"2436","DOI":"10.1007\/s00259-022-05693-0","volume":"49","author":"C Mingels","year":"2022","unstructured":"Mingels C et al (2022) Diagnostic accuracy of [18F] PSMA-1007 PET\/CT in biochemical recurrence of prostate cancer. Eur J Nucl Med Mol Imaging 49(7):2436\u20132444","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"212_CR32","doi-asserted-by":"crossref","unstructured":"Mittlmeier LM et al (2021) Feasibility of different tumor delineation approaches for 18F-PSMA-1007 PET\/CT imaging in prostate cancer patients. Front Oncol, : p. 1612","DOI":"10.1055\/s-0041-1726838"},{"issue":"6","key":"212_CR19","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1097\/RLU.0000000000003558","volume":"46","author":"C Onal","year":"2021","unstructured":"Onal C et al (2021) Oligometastatic bone disease in castration-sensitive prostate Cancer patients treated with stereotactic body Radiotherapy using 68Ga-PSMA PET\/CT: TROD 09\u2009\u2013\u2009004 study. Clin Nucl Med 46(6):465\u2013470","journal-title":"Clin Nucl Med"},{"issue":"November","key":"212_CR21","first-page":"1","volume":"11","author":"DE Oprea-Lager","year":"2021","unstructured":"Oprea-Lager DE et al (2021) Bone metastases are measurable: the role of whole-body MRI and Positron Emission Tomography. Front Oncol 11(November):1\u201318","journal-title":"Front Oncol"},{"issue":"1","key":"212_CR42","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.eururo.2015.07.004","volume":"69","author":"P Ost","year":"2016","unstructured":"Ost P et al (2016) Progression-free Survival following stereotactic body radiotherapy for oligometastatic prostate Cancer Treatment-naive recurrence: a multi-institutional analysis. Eur Urol 69(1):9\u201312","journal-title":"Eur Urol"},{"issue":"5","key":"212_CR46","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1200\/JCO.2017.75.4853","volume":"36","author":"P Ost","year":"2018","unstructured":"Ost P et al (2018) Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence: a prospective, randomized, multicenter phase II trial. J Clin Oncol 36(5):446\u2013453","journal-title":"J Clin Oncol"},{"issue":"25","key":"212_CR13","doi-asserted-by":"publisher","first-page":"2830","DOI":"10.1200\/JCO.20.00818","volume":"38","author":"DA Palma","year":"2020","unstructured":"Palma DA et al (2020) Stereotactic ablative radiotherapy for the comprehensive treatment of oligometastatic cancers: long-term results of the SABR-COMET phase II randomized trial. J Clin Oncol 38(25):2830\u20132838","journal-title":"J Clin Oncol"},{"issue":"4","key":"212_CR7","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.eururo.2019.01.049","volume":"77","author":"M Perera","year":"2020","unstructured":"Perera M et al (2020) Gallium-68 prostate-specific membrane Antigen Positron Emission Tomography in Advanced prostate Cancer\u2014updated diagnostic utility, sensitivity, specificity, and distribution of prostate-specific membrane Antigen-avid lesions: a systematic review and Meta. Eur Urol 77(4):403\u2013417","journal-title":"Eur Urol"},{"issue":"3","key":"212_CR38","doi-asserted-by":"publisher","first-page":"395","DOI":"10.2967\/jnumed.122.264334","volume":"64","author":"TE Phelps","year":"2023","unstructured":"Phelps TE et al (2023) Predicting outcomes of Indeterminate Bone lesions on 18F-DCFPyL PSMA PET\/CT scans in the setting of high-risk primary or recurrent prostate Cancer. J Nucl Med 64(3):395\u2013401","journal-title":"J Nucl Med"},{"issue":"5","key":"212_CR16","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1001\/jamaoncol.2020.0147","volume":"6","author":"R Phillips","year":"2020","unstructured":"Phillips R et al (2020) Outcomes of Observation vs Stereotactic Ablative Radiation for oligometastatic prostate Cancer: the ORIOLE phase 2 Randomized Clinical Trial. JAMA Oncol 6(5):650\u2013659","journal-title":"JAMA Oncol"},{"issue":"7","key":"212_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12032-020-01385-7","volume":"37","author":"DK Reyes","year":"2020","unstructured":"Reyes DK et al (2020) Multidisciplinary total eradication therapy (TET) in men with newly diagnosed oligometastatic prostate cancer. Med Oncol 37(7):1\u201312","journal-title":"Med Oncol"},{"issue":"1","key":"212_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13014-021-01849-8","volume":"16","author":"P Rogowski","year":"2021","unstructured":"Rogowski P et al (2021a) Outcomes of metastasis-directed therapy of bone oligometastatic prostate cancer. Radiat Oncol 16(1):1\u201311","journal-title":"Radiat Oncol"},{"key":"212_CR26","doi-asserted-by":"crossref","unstructured":"Rogowski P et al (2021b) Outcome after PSMA-PET\/CT-based salvage radiotherapy for nodal recurrence after radical prostatectomy. European Journal of Nuclear Medicine and Molecular Imaging","DOI":"10.1016\/S0167-8140(21)07191-7"},{"issue":"8","key":"212_CR10","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1007\/s00066-022-01925-2","volume":"198","author":"P Rogowski","year":"2022","unstructured":"Rogowski P et al (2022) Radiotherapy in oligometastatic prostate cancer\u2014a pattern of care survey among members of the German Society for Radiation Oncology (DEGRO). Strahlenther Onkol 198(8):727\u2013734","journal-title":"Strahlenther Onkol"},{"key":"212_CR25","doi-asserted-by":"crossref","unstructured":"Seifert R et al (2023a) Second version of the prostate cancer molecular imaging standardized evaluation framework including response evaluation for clinical trials (PROMISE V2). Eur Urol","DOI":"10.1016\/j.eururo.2023.02.002"},{"issue":"5","key":"212_CR36","doi-asserted-by":"publisher","first-page":"738","DOI":"10.2967\/jnumed.118.215434","volume":"64","author":"R Seifert","year":"2023","unstructured":"Seifert R et al (2023b) Unspecific 18F-PSMA-1007 bone uptake evaluated through PSMA-11 PET, bone scanning, and MRI triple validation in patients with biochemical recurrence of prostate cancer. J Nucl Med 64(5):738\u2013743","journal-title":"J Nucl Med"},{"issue":"3","key":"212_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H et al (2021) Global Cancer statistics 2020: GLOBOCAN estimates of incidence and Mortality Worldwide for 36 cancers in 185 countries. Cancer J Clin 71(3):209\u2013249","journal-title":"Cancer J Clin"},{"key":"212_CR14","doi-asserted-by":"crossref","unstructured":"Tang C et al (2023) Addition of Metastasis-Directed therapy to intermittent hormone therapy for oligometastatic prostate Cancer: the EXTEND phase 2 Randomized Clinical Trial. JAMA Oncol","DOI":"10.1001\/jamaoncol.2023.0161"},{"issue":"2","key":"212_CR18","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1007\/s00120-022-01927-z","volume":"62","author":"C Thomas","year":"2023","unstructured":"Thomas C, Schrader A (2023) Neue S3-Leitlinie Prostatakarzinom 2021 (Version 6.2)\u2013Was hat sich beim fortgeschrittenen Prostatakarzinom ge\u00e4ndert? Die Urologie 62(2):171\u2013175","journal-title":"Die Urologie"},{"key":"212_CR48","doi-asserted-by":"crossref","unstructured":"Vaz S et al (2020) Influence of androgen deprivation therapy on PSMA expression and PSMA-ligand PET imaging of prostate cancer patients. Springer, pp 9\u201315","DOI":"10.1007\/s00259-019-04529-8"},{"key":"212_CR24","doi-asserted-by":"crossref","unstructured":"World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA, (2013) 310(20): p. 2191\u20132194","DOI":"10.1001\/jama.2013.281053"},{"issue":"6","key":"212_CR4","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1111\/cpf.12480","volume":"38","author":"HD Zacho","year":"2018","unstructured":"Zacho HD et al (2018) 68Ga-PSMA PET\/CT for the detection of bone metastases in prostate cancer: a systematic review of the published literature. Clin Physiol Funct Imaging 38(6):911\u2013922","journal-title":"Clin Physiol Funct Imaging"},{"key":"212_CR51","doi-asserted-by":"crossref","unstructured":"Zacho HD et al (2020) Added value of 68Ga-PSMA PET\/CT for the detection of bone metastases in patients with newly diagnosed prostate cancer and a previous 99mTc bone scintigraphy. EJNMMI Res, 10(1)","DOI":"10.1186\/s13550-020-00618-0"}],"container-title":["EJNMMI Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41824-024-00212-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s41824-024-00212-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41824-024-00212-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,20]],"date-time":"2024-08-20T18:08:44Z","timestamp":1724177324000},"score":1,"resource":{"primary":{"URL":"https:\/\/ejhi.springeropen.com\/articles\/10.1186\/s41824-024-00212-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,19]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["212"],"URL":"https:\/\/doi.org\/10.1186\/s41824-024-00212-w","relation":{},"ISSN":["3005-074X"],"issn-type":[{"value":"3005-074X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,19]]},"assertion":[{"value":"4 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 May 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 August 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This retrospective analysis was performed in compliance with the principles of the Declaration of Helsinki and its subsequent amendments and was approved by the local Ethics Committee of the LMU Medical Faculty (approval number 19\u2013361). Consent to participate was waived due to the retrospective nature of our study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Lena M. Unterrainer received personal fees from Novartis Radiopharmaceuticals, Astellas Pharma Inc., Telix Pharmaceuticals and is on the advisory board of Telix Pharmaceuticals. All other authors declare that they have no conflicts of interest or competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"25"}}